Back to Search
Start Over
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
- Source :
- Bone. 120
- Publication Year :
- 2018
-
Abstract
- Abaloparatide is a 34-amino acid peptide that selectively binds to the RG conformation of the parathyroid hormone receptor type 1. It was developed for the treatment of women with postmenopausal osteoporosis at high risk of fracture. In ACTIVE, an 18-month phase 3 study (NCT01343004), abaloparatide increased bone mineral density (BMD), decreased the risk of vertebral and nonvertebral fractures compared with placebo, and decreased the risk of major osteoporotic fractures compared with placebo and teriparatide. Here, we report a prospective, exploratory BMD responder analysis from ACTIVE.Proportions of patients experiencing BMD gains from baseline of0%,3%, and6% at the total hip, femoral neck, and lumbar spine at 6, 12, and 18 months of treatment were compared among the placebo, abaloparatide, and teriparatide groups in ACTIVE. Responders were defined prospectively as patients experiencing BMD gains at all 3 anatomic sites.At months 6, 12, and 18, there were significantly more3% BMD responders in the abaloparatide group compared with placebo and teriparatide: month 6, 19.1% vs 0.9% for placebo and 6.5% for teriparatide; month 12, 33.2% vs 1.5% and 19.8%; month 18, 44.5% vs 1.9% and 32.0% (P 0.001 for all comparisons of abaloparatide to placebo and to teriparatide). Findings were similar for the0% and6% responder thresholds.In postmenopausal women with osteoporosis, a significantly greater proportion of patients treated with abaloparatide experienced increases in BMD than did those treated with placebo or teriparatide.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Histology
Physiology
Endocrinology, Diabetes and Metabolism
Abaloparatide
Osteoporosis
Urology
Phases of clinical research
030209 endocrinology & metabolism
Postmenopausal osteoporosis
Placebo
Bone and Bones
Placebos
03 medical and health sciences
0302 clinical medicine
Bone Density
Teriparatide
medicine
Humans
Femoral neck
Aged
Bone mineral
business.industry
Parathyroid Hormone-Related Protein
medicine.disease
030104 developmental biology
medicine.anatomical_structure
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 18732763
- Volume :
- 120
- Database :
- OpenAIRE
- Journal :
- Bone
- Accession number :
- edsair.doi.dedup.....1a62d32aad58898a544c269d6f1edc4f